Prerpints.org logo

You are currently viewing a beta version of our website. If you spot anything unusual, kindly let us know.

Leave Feedback
Preprint
Review

TGF- β Signaling Pathways in the Development of Diabetic Retinopathy

Altmetrics

Downloads

104

Views

41

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

24 January 2024

Posted:

26 January 2024

You are already at the latest version

Alerts
Abstract
Diabetic retinopathy (DR), a prevalent complication of diabetes mellitus affecting a significant portion of the global population, has long been viewed primarily as a microvascular disorder. However, emerging evidence suggests that it should be redefined as a neurovascular disease with multifaceted pathogenesis rooted in oxidative stress and advanced glycation end products. The transforming growth factor-β (TGF-β) signaling family has emerged as a major contributor to DR pathogenesis due to its pivotal role in retinal vascular homeostasis, endothelial cell barrier function, and pericyte differentiation. However, the precise roles of TGF-β signaling in DR remain incompletely understood, with conflicting reports on its impact in different stages of the disease. Additionally, the BMP subfamily within the TGF-β superfamily introduces further complexity, with BMPs exhibiting both pro- and anti-angiogenic properties. Furthermore, TGF-β signaling extends beyond the vascular realm, encompassing immune regulation, neuronal survival, and maintenance. The intricate interactions between TGF-β and reactive oxygen species (ROS), non-coding RNAs, and inflammatory mediators have been implicated in the pathogenesis of DR. This review delves into the complex web of signaling pathways orchestrated by the TGF-β superfamily and their involvement in DR. A comprehensive understanding of these pathways may hold the key to developing targeted therapies to halt or mitigate the progression of DR and its devastating consequences.
Keywords: 
Subject: Medicine and Pharmacology  -   Ophthalmology

1. Introduction

Diabetic retinopathy (DR) is a complication of diabetes mellitus (DM) affecting 22% of the world’s population [1]. DR was previously understood to be a microvascular disease, however, new evidence has now shown it to be a neurovascular disease with complex pathogenesis originating from oxidative stress and advanced glycation end products [2,3,4]. The accumulation of these products leads to immune dysfunction as well as neuronal and vascular disruption and results in a disease in which multiple cell types and signaling pathways of the retina become involved [3,5,6]. Vascular dysfunction has a prime role in DR and has been studied extensively. Angiogenic pathology is found to appear early in DR as microaneurysms, small outpouchings from retinal capillaries, dot intraretinal hemorrhages, and cotton wool spots [7]. These changes can ultimately progress to vision-threatening consequences like diabetic macular edema, neovascularization, and tractional retinal detachment [4,7].
Currently, non-proliferative diabetic retinopathy (NPDR) management varies depending on the presence of macular edema [8]. NPDR without macular edema is managed by counseling patients to maintain an HbA1c below 7%. When diabetic macular edema (DME) is present, first-line treatment of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is started to target the vascular permeability caused by the increase in VEGF production. In cases of proliferative diabetic retinopathy (PDR), this anti-VEGF treatment is used to control neovascularization. This is often followed by pan-retinal photocoagulation laser therapy to regress new blood vessels and ablate ischemic tissue. Vitrectomies are employed in the presence of a tractional retinal detachment or persistent, large vitreous hemorrhage. Though intravitreal anti-VEGF is by far the most used therapy to treat PDR and DME it has been shown that DME patients often have a less robust response to anti-VEGF therapy compared to patients treated for neovascular age-related macular degeneration or retinal vein occlusion [9]. Serum studies show that a large percentage of DME patients have a relatively low to normal level of VEGF, and therefore experience persistent, vision-limiting DME despite frequent intravitreal anti-VEGF therapy [10]. Thus, other mechanisms of DR should be explored and potentially targeted for treatment.
Current evidence suggests the TGF-β signaling family may be a potential target for the treatment of DR, as it is crucial in a wide number of homeostatic functions in the retinal vasculature, including endothelial cell barrier function and pericyte differentiation [7]. Both endothelial cells and pericytes manage the vascular environment within the retina, and thus communication between both cell types is essential for function.10 Communication is carried out by a multitude of signaling molecules, many of which belong to the TGF-β signaling family. A study done on mice with a conditional deletion of TGF-β found that the resulting decrease in TGF-β led to the onset of the same retinal phenotype as DR, including microaneurysms, retinal hemorrhages, and cotton wool spots [7]. This shows that disturbance of the delicate balance of these pathways is implicated in DR, as well as other similar diseases. Though changes in TGF-β expression in early DR are believed to act protectively on the retinal microvasculature, these changes over time appear to lead to endothelial cell proliferation and pericyte dedifferentiation [7,11]. Because of its role in vascular homeostasis and pathology, as well as the recent research exploring the detrimental effects caused by dysregulation of TGF-β in the context of diabetic retinal tissues, TGF-β is proposed to be a critical factor in microvascular abnormalities caused by DM [11].
Despite the crucial role of TGF-β in homeostasis and its implication in DR pathogenesis, its precise roles remain incompletely studied [7,12]. However, current research is being done to identify specific TGF-β ligands associated with certain diseases, as well as the proposed mechanisms precipitating the disease state [13]. In association with receptors and intracellular signaling, the various members TGF-β signaling family have been shown to either diminish or enhance angiogenesis [12,14,15]. At times, previous findings contradict, further indicating TGF-β signaling is not well understood in the pathogenesis of DR [12]. This necessitates the further exploration of the effects of altered TGF-β signaling on the retinal vasculature. This review aims to summarize the current understanding of TGF-β signaling pathways in vascular pathology in DR. It should be emphasized although TGF-β pathways influence numerous cell types and gene expressions in DR, these varied mechanisms are not the focus of this review and are discussed only briefly. The major pathways of DR development by the TGF-β family described in this review is illustrated in Figure 1.

2. An Overview of TGF-β Signaling Pathways

The TGF-β superfamily comprises more than 30 members, including TGF-β isoforms, bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs), activins, inhibins, anti-Mullerian hormone, and Nodal [13,16]. They bind with several transmembrane receptor classes including activin-like kinases (ALKs), TGF-β receptors (TGFBRs), and BMP receptors (BMPRs) [13]. These ligand-receptor classes are widespread throughout various organs and tissues and are involved in embryonic development as well as homeostatic maintenance, inflammation, and various pathologies [16]. They exert fine control of a variety of tissue types in a context-dependent manner [13].
The TGF-β superfamily canonical signaling cascade begins when a ligand binds to a dimer of type II transmembrane receptors [16]. These type II receptors then recruit a dimer of type I receptors, forming a heterotetramer. Following this, type II receptors phosphorylate type I receptors, which removes the inhibitory FKBP12 protein from the type I receptor, allowing for the attachment of intracellular proteins such as SMADs. SMADs will then be phosphorylated in a cascade to form complexes and enter the nucleus to influence transcription [16,17]. There are three categories of SMADs: regulatory (R-SMAD), common mediator (co-SMAD), and inhibitory (I-SMAD). These SMADs form complexes with each other and the unique composition of SMADs affects which genes are targeted [16,18].
TGF-β can also activate a non-canonical pathway, in which receptor activation results in activation of mitogen-activated protein kinase (MAPK) pathways, IκB kinase (IKK), phosphatidylinositol-3 kinase (PI3K) and Akt, or Rho family GTPases [9,19]. These intracellular signals may then act independently of SMADs or interfere with SMADs and induce further signaling cascades which will translocate to the nucleus to influence transcription. [17,18].
To help regulate these pathways, TGF-β may interact with regulatory type III receptors, betaglycan and endoglin. These receptor types consist of large extracellular components and small intracellular components with no kinase activity [16,20]. Betaglycan acts as a ligand reservoir, whereas endoglin modulates the response of ALK1 to shear stress from blood flow and thus regulates the angiogenic response [16]. Though the mechanism by which endoglin supports endothelial cell function remains unclear, studies on endoglin-null and endoglin mutated mice have demonstrated endoglin’s crucial role in supporting this activity [20].
BMPs, a subfamily of TGF-β, appear to signal through similar canonical and non-canonical pathways as other members of the superfamily [9]. These proteins are essential in numerous developmental processes, evident by studies on different BMP knock-out mice resulting in complications like abnormal morphogenesis of various organs [21]. BMPs bind to BMP type I receptors (BMPR1) and BMP type II receptors (BMPR2) to activate the SMAD pathway or the SMAD-independent pathway. BMPR1 receptors include members of the ALK group such as ALK1, ALK2, ALK3, ALK4, and ALK6. These receptors are widely expressed in various cell types, as well as the endothelial-specific ALK-1. BMPR2 includes BMPR-II, ActRIIa, and ActRIIb and is constitutively active [9,21].
Of the numerous members of the TGF-β signaling pathway, certain ligands and receptors appear more closely related to angiogenesis in both homeostasis and pathology [16]. For example, studies on TGF-β1 knockout mice have demonstrated the role of the TGF-β1 ligand in maintaining the blood-retinal barrier. TGF-β1 is present in retinal ganglion cells (RGC), photoreceptors, pericytes, smooth muscle cells, and microglia. Increased levels of TGF-β1 have been found in DR [16,22]. Some animal models have described that when engaging with the ALK1 receptor, TGF-β1 has pro-angiogenic effects. In contrast, the interaction between TGF-β1 and ALK5 has shown to be anti-angiogenic [16]. ALK1 appears to be strongly expressed in embryogenesis, however decreases sharply in adult life until angiogenic stimulation is present. Similarly, endoglin has been shown to mitigate the activity of different TGF-β pathways to promote angiogenesis [16,23,24]. Because of this, endoglin targeting has become a potential method of inhibiting angiogenesis [24]. BMP9 and BMP10 bind with high affinity to ALK1 and endoglin to signal quiescence, depressing the angiogenic effects of VEGF [16,25]. BMP2 and BMP4 have been found to be crucial in vasculogenesis.
It should be noted the above-described signaling model is a simplified overview. In addition to various ligands, receptors, and intracellular signaling proteins, co-receptors are also present for fine control [18]. These include betaglycan and endoglin as well as many others such as repulsive guidance molecules (RGMs), BAMBI, and crypto. Co-receptors may also have separate functions as structural proteins or ligands initiating separate signaling cascades. These co-receptors are incompletely studied and are not the focus of this review.

3. Association of TGF-β signaling pathways in DR

TGF-β signaling is an established player in maintaining retinal capillaries, and TGF-β1 has been identified as a contributing factor in the pathogenesis of DR [7,26]. TGF-β1 is known to activate in response to ROS, resulting in eventual proliferation of endothelial cells, angiogenesis, and blood-retina barrier disruption [27]. Inhibition of the TGF-β signaling pathway has been shown to decrease VEGF production following hypoxic states in vitro [28]. To understand the relationship between the stage of disease and TGF-β1 serum levels, one study obtained serum levels of TGF-β1 from those with NPDR and PDR diagnoses. Within these diagnosis groups, people were further divided into aflibercept treatment and non-treatment groups. Data analysis between these categories found TGF-β1 to be three times higher in patients with exacerbated PDR than those with controlled PDR and therefore predictive of disease severity and control [23]. Interestingly, patients with NPDR who had received aflibercept treatment in the past week showed lower levels of TGF-β1 than NPDR patients without aflibercept treatment. Additionally, higher TGFβ-1 levels were found to correlate with HbA1c levels, duration of diabetes, and progression of DR. These findings make TGF-β1 a potential predictor of disease progression from NPDR to PDR.
Other studies have shown similar findings. A study on TGF-β1 and -β2 levels in aqueous humor also found elevated levels in patients with NPDR compared to control patients [29]. Levels of TGF-β1 are also seen elevated in the vitreous humor of PDR patients compared to controls [30]. Certain polymorphisms of the TGF-β1 gene have also been studied as potential DR risk factors: it has been found that +869T/ C(L10P) polymorphisms in the TGF-β1 gene may be a strong DR risk factor, whereas the 2509T/C polymorphism is not associated with DR risk [31].
TGF-β levels have also been found to correlate with the increased expression of long non-coding RNA of myocardial infarction associated transcript (lncRNA-MIAT) [32]. LncRNA-MIAT, a known mediator in microvascular dysfunction, has been shown to be upregulated and reduce viability in adult retinal pigment epithelial cells (ARPE-19) under hyperglycemic conditions. When these cells are treated with a TGF-β inhibitor, these effects are dampened, suggesting TGF-β may reduce the viability of epithelial cells in the setting of diabetes. The long non-coding RNA nuclear-enriched abundant transcript 1 (lncRNA-NEAT1) has also been found to trigger TGF-β1 and VEGF expression with associated findings of apoptosis and oxidative stress in diabetic mice retina [33]. This implies silencing the expression of lncRNA-NEAT1 could reduce the hyperglycemic stress on retinal endothelial cells.
Interestingly, the correlation between TGF-β and DR is not completely uniform. At least one study has found serum concentrations of TGF-β1 to be higher in diabetes without apparent DR than those with NPDR and PDR [34]. Likewise, studies regarding TGF-β gene expression via non-coding RNAs have revealed mixed associations. One study mirrored previous findings by measuring an increase in TGF-β to various microRNAs in the context of proliferative DR [35]. However, in a different study utilizing the mouse model, introduced amniotic mesenchymal stem cells migrated to hypoxic retinal tissue and reduced excessive neovascularization through release of TGF-β1 [15]. Use of siRNA to block this pathway resulted in negation of this effect. These results highlight that TGF-β is necessary to maintain the blood-retinal barrier, though a pathological excess expression of TGF-β may result in vasculopathy itself.
TGFβ-1 is also known to affect endothelial cell proliferation and migration, and evidence suggests total lack of TGF-β may also be detrimental to vascular integrity [7]. In newborn mice, total inhibition of TGFBRII signaling was shown to produce characteristics reminiscent of DR. The same study found lack of retinal TGF-β resulted in dedifferentiation of microvascular pericytes, unregulated proliferation of vascular endothelium with reduced barrier function, and reactive microglia. Poor vascular function in the mouse retina led to retinal hypoxia and induction of angiogenic molecules and further neovascularization. This suggests the TGF-β maintenance mechanism fails in DR and indicates that signaling pathways must be further understood if it is to be a target for future therapy.
It is possible changes in ALK1/ALK5 expression modulates TGF-β response in pathological conditions [11]. Using an ALK5 inhibitor, one study on rats found that inhibition of ALK-5 signaling resulted in leaky vessels with characteristic features of DR in the embryo, newborn, and adult rate groups. The same ALK5 inhibitor used on diabetic rats showed prominent signs of DR. Therefore, TGF-β/ALK5 signaling is believed to be important for protection from hyperglycemic damage, especially in the setting of diabetes without DR. Similarly, soluble expression of endoglin has been shown to promote TGF-β1/ALK-1 signaling and interfere with TGF-β1/ALK-5, therefore increasing fibro-neovascularization, angiogenesis, and arteriovenous malformations. Altogether, this activity promotes endothelial proliferation [7,36,37]. Under hyperglycemic conditions, BMP9/ALK1 signaling was shown to be disrupted in human umbilical endothelial cells, and inversely, signaling through ALK1 solidifies the integrity of the vascular barrier by blocking VEGF-inducting phosphorylation of VE-cadherin and by solidifying occludin junctions independently of VEGF [4]. These results suggest that an incremental increase in TGF-β signaling is a protective mechanism, whereas an insufficient response to TGF-β may cause disease progression [11].
Though TGF-β1 is the main isoform studied in DR, other isoforms of TGF-β have also been associated with DR [38]. One study found that the TGF-β2 isoform was the only detectable isoform in the healthy retina and did not change in concentration with DR progression, indicating that it may be an auxiliary mechanism for DR pathology [34]. A study on human retinal pigment epithelial cells showed that TGF-β2, both independently and in combination with TNF-α, is associated with retinal neovascularization and an increase in VEGF. Moreover, blockage of the TGF-β2 signaling pathway by miR-200a-3p, a microRNA shown to be downregulated in diabetic rat retinal tissue, suppressed DR progression in diabetic rats, further establishing the role of TGF-β2 overexpression in the pathogenesis of DR [39,40]. At least one study has found TGF-β3 to also be elevated in PDR [41]. Another study on diabetic rats showed elevated levels of connective tissue growth factor (CTGF), VEGF, and TGF-β2 [38]. The level of these factors showed higher levels in more severe cases of DR. When CTGF was targeted, the levels of VEGF and TGF-β2 diminished and apoptosis of retinal cells was reduced, providing evidence of an association between these TGF-β2 and the pathophysiology of DR.
Thus, as evidenced by mixed results from different reports in the literature, the association between TGF-β and angiogenesis in DR is complex. This is likely due to the many intracellular effectors, co-receptors, cell types, and individual gene expressions with which TGF-β interacts. As DR is an inflammatory disease, additional pathways for angiogenesis may originate in the immune response [16]. Macrophages are a significant source of TGF-β1 in DR, and TGF-β signaling is not only necessary for vascular maintenance but also for immune response in the retina [16,30]. Studies exploring interactions between immune cells and vasculature in the environment of pathological retina may be beneficial in elucidating these associations.

4. Association of BMP signaling pathways with DR

BMPs are a subfamily of the TGF-β superfamily and have been implicated in tumor growth, angiogenesis, and tissue and glucose homeostasis [42]. They are closely connected to vascular maintenance and survival [25]. The precise roles that BMP plays in vascular homeostasis and pathology remains unclear and is a topic of continued study in DR pathogenesis [9].
BMP9 and BMP10 bind with high affinity to ALK1 via BMP type II receptors to promote vascular quiescence and stability [4,25]. Interestingly, BMP9 seems to improve vascular barrier function even in mice with total knockout of ALK1 [9]. However, BMP2, BMP4, and BMP6 through signaling of ALK2, ALK3, and ALK6 seem to each have necessary roles in angiogenesis [16]. BMP2 is known to induce retinal endothelial barrier dysfunction by activation of both canonical and non-canonical pathways, leading to induction of VEGF from retinal epithelial cells and Muller cells, induction of angiopoietin 1, oxidative stress, and inflammatory responses [9,16]. Furthermore, this BMP2 pathway has been shown to be inhibited by BMPR inhibitors [9]. BMP2 and VEGF have also been shown to engage in positive feedback with each other at both RNA and protein levels [9,42].
Studies investigating the effects of BMP4 have found it to have both anti-angiogenic effects and pro-angiogenic effects [9,16]. To explore the BMP4 signaling mechanisms, one study analyzed BMP4 levels in ARPE cells and found that cells treated with excess glucose expressed significantly greater levels of BMP4 than those treated with a physiological amount of glucose [43]. The same study then treated ARPE cells with exogenous BMP4 and found an increase in VEGF production in a time and dose-dependent manner. These results establish an association between elevated BMP4 levels and angiogenesis. However, this conflicts with previous studies done in human retinal pigment epithelial cells where there was no discernable association between BMP4 and VEGF [44]. As for BMP9, one study investigated diabetic mice with sustained overexpression of BMP9 and found a significant decrease in retinal vascular permeability by curbing hyperglycemia-induced occludin decrease [4].
BMP has also been found to be regulated by an extracellular glycoprotein called BMP endothelial cell precursor-derived regulator (BMPER) [45]. In low concentrations, BMPER has been found to promote the migration of endothelial cells [9]. This has been demonstrated by BMPER knockout mice showing significant endothelial permeability and, therefore, prominent vascular leakage. Conversely, high concentrations of BMPER have been found to inhibit this migration. Therefore, BMPER may be responsible for a dose-dependent fine-tuning of BMP activity. An in vitro study of human retinal endothelial cells has found BMPER to be significantly reduced in hyperglycemic conditions, which may explain BMP2 upregulation in diabetic retinas [42]. This illuminates the potential role of BMPER downregulation in the pathogenesis of DR.

5. Association of TGF-β with Immune Cells in DR

Both the expression of TGF-β by macrophages and the effects of TGF-β on macrophages have been implicated in the pathogenesis of DR [46]. The effects of TGF-β on macrophages has shown to result in anti-inflammatory effects, specifically through SMAD6 and SMAD7. One pathway explored has been TGF-β’s ability to promote the action of SMAD6 to degrade MYD88, which is necessary for TLR activation of NF-κB. SMAD7 activation has been shown to inhibit TNF-mediated inflammatory pathways through complexing with TAB2 and TAB3 molecules [47].
These findings of TGF-β promoting anti-inflammatory effects is at odds with what has been the observed function of TGF-β expressed by macrophages, specifically in diabetic retinas. To investigate these pathways, Mondragon et al. experimented with Rhesus monkey retinal endothelial cells (RhREC) stimulated by macrophage-derived TGF-β. [48]. The results showed significant increase in BIGH3 expression and BIGH3-mediated apoptosis of RhRECs, demonstrating the apoptotic effects of macrophage-derived TGF-β on RECs. Further demonstrating this relationship, RhRECs were treated with media conditioned by macrophages cultured under diabetic conditions, which also showed a significant increase in BIGH3 expression. When RhRECs being treated with TGF-β were cotreated with antibodies against TGF-β, BIGH3, or TGF-βRI, apoptosis was significantly blunted.
Histopathologic investigation of post-mortem retinal tissue from a donor with a 7-year history of Type II DM with NPDR was done to see the mechanism of BIGH3 in early DM pathogenesis [46]. It was found that that the retinal arterioles had significant levels of BIGH3. Perivascular presence of microglia and macrophages were also found. This offers an in vivo representation of the role of TGF-β-induced retinal changes in the diabetic retina before proliferation takes place.
The relationship between regulatory T-cells (Tregs) and TGF-β in the pathogenesis of DR has been one of particular interest, as well. Tregs are known for their immunoregulatory activity, and, in the setting of diabetes, it has been shown that Treg levels are decreased as compared to patients without diabetes [49,50]. The differentiation of Tregs is dependent on the transcription factor FOXP3, demonstrated by various studies on FOXP3 knockout mice resulting multi-organ autoimmune damage [51]. FOXP3 activity is dependent on TGF-β, and in conditions of low TGF-β, Treg differentiation is notably diminished [50]. Micro-RNA (miRNA), specifically miR-155, have been shown to modulate TGF-β activity by inhibiting SMAD signaling [52]. Therefore, it has been believed that increased miR-155 may attenuate Treg activity and, consequently, it’s anti-inflammatory effects. To study this, Yang et al. split Type II DM study participants into three groups, defined by participants with PDR, participants with NPDR, and participants with no apparent retinopathy (NAR). A control group of non-diabetic participants without retinopathy was also studies. Measurements of the participants TGF-β, Treg, and miR-155 levels found that the diabetic patients had a significantly lower level of Tregs, and participants with PDR had significantly lower levels of Tregs than those with NPDR, showing an inverse relationship between Treg levels and severity of retinopathy. This relationship was also seen between TGF-β levels and severity of retinopathy. However, levels of miR-155 showed a direct relationship with severity of retinopathy, with PDR participants having the highest levels of miR-155 and the control group having the lowest. The results support the hypothesis that miR-155 impairs Tregs and TGF-β activity in the pathogenesis of diabetic retinopathy [52].

6. The Role of TGF-β in DR-related Neurodegeneration

Neurodegeneration of the retina is one of the earliest findings in diabetic retinopathy, often identifiable before vascular abnormalities are present [53]. This is a result of a myriad of cellular and molecular mechanisms, most well-known of which include an upregulation of pro-apoptotic proteins and elevated ROS in the diabetic retinal neuronal cells. As mentioned previously, TGF-β signaling pathways are not limited to vascular control. TGF-β signaling plays important roles in immune regulation, neuronal survival, and neuronal maintenance. However, research regarding the precise mechanisms and effects of each TGF-β molecule remains inconclusive and, at times, contradictory. Experiments on RGCs under oxidative stress have been used to illustrate the mechanisms of TGF-β1 and TGF-β2 combating cellular oxidative stress [54]. These experiments demonstrate TGF-β’s ability to promote the expression of neuroprotective and antioxidative proteins like nuclear factor erythroid-2 related factor (Nfr2), Kelch-like ECH-associated protein 1 (Keap1), aldehyde dehydrogenase 3A1 (ALDH3A1), and heme oxygenase-1 (HO-1). One study found TGF-β1 and TGF-β2 to limit damage from hyperglycemia in RGCs [55]. In this study, hyperglycemic conditions increased ROS within RGCs in vitro and resulted in irreversible epigenetic changes including histone modifications, DNA methylation, and non-coding RNAs. When TGF-β1 and TGF-β2 were knocked down, RGCs proliferated less and were more sensitive to oxidative stress. This is important in the setting of diabetes because ROS is a major contributor to the cellular damage that takes place in DR. By contrast, separate studies have shown the AGE/RAGE axis seen in diabetes to increase TGF-β presence [18,56]. This has the downstream consequences of increased ROS production, suppressed antioxidant mechanisms, and increased expression of Nox enzymes.

7. Other Association of TGF-β superfamily signaling pathway in DR

One study explored the effects of altered TGF-β2 levels on retinal cells by analyzing ARPE-19 cells treated with acrolein, a known pollutant that contributes to macular degeneration. These treated ARPE-19 cells demonstrated an increase in secreted VEGF and TGF-β2, as well as reduced viability of the treated cells. The study then repeated the treatment on a new set of ARPE-19 cells, followed by the administration of a SMAD3 inhibitor. This inhibitor was intended to inhibit the effects of the increased TGF-β2. This addition saved about 48% of cells from senescence. A major mechanism of cell death may therefore be related to increase in secreted TGF-β2 [57].
This effect may not be the same for all retina cells, however. Human retina pericytes (HRP) have been shown to secrete increased levels of VEGF and TGF-β2 in the setting of hyperglycemia. HRP appear to increase in cell numbers and decrease VEGF secretion when exposed to elevated TGF-β2. A study on HRP exposed to hyperglycemic conditions showed the cells to be refractory to TGF-β2 effects compared to those in euglycemic conditions. Because elevated TGF-β2 levels have previously been shown to cause pericyte proliferation, these findings suggest that in the diabetic retina, elevated glucose levels may prevent TGF-β2 from proliferating pericytes, leaving the HRP more susceptible to damage by other mechanisms. TGF-β2 has also previously been shown to decrease VEGF levels, so reduced TGF-β2 activity allows for less VEGF regulation and, therefore, increases angiogenesis [58].
Emerging evidence has also shown that expression of Nox enzymes and mitochondrial dysfunction engage in a positive feedback loop with TGF-β. Mitochondria produce ROS which then stimulates increased TGF-β production. This results in an increase in Nox expression in response and, therefore, a greater production of ROS. NOX-generated ROS increase mitochondrial dysfunction and further produce ROS. Redox imbalances also activate latent TGF-β1 and induce TGF-β1 gene expression. Complete blockade of TGF-β has been shown to damage ocular tissue by unregulated immune responses [18,22].
The BMP subfamily is also involved in many mechanisms outside of vasculature with relevance to DR. BMP2 expression is induced by ROS, which in turn have been previously correlated with hyperglycemia-induced vascular calcification [59]. Dyslipidemia in diabetes has been shown to increase BMP4, leading to an increase in Nox1, as well as induction of inflammation by Cox-2 and VCAM-1. BMP2 also releases inflammatory markers to induce adhesion of endothelium to leukocytes and induces oxidative stress in human retinal endothelial cells (HRECs) [42,60]. BMP4 has been found to be overexpressed in Muller cells, stimulated by hyperglycemia, and reduced by regulatory non-coding RNAs [60]. This is believed to contribute to DR pathogenesis.
In addition to TGF-β isoforms and BMPs, many other TGF-β family members may also be involved in DR. One such member is growth differentiating factor 15 (GDF-15), whose precise intracellular mechanisms are not yet known [61]. GDF-15 expression increases in ischemic states and has been shown to be associated with cardiovascular injury and inflammation, including retinal vascular pathologies such as DR [61,62]. In fact, previous studies have demonstrated that serum concentrations of GDF-15 can be positively correlated with DR and may hold value as a biomarker for identifying the disease [62]. GDF-15 are secreted by cells such as endothelial cells, vascular smooth muscle cells, and macrophages, and may be an indication of microvascular damage. An in vitro study with human umbilical vein endothelial cells (HUVEC) showed GDF-15 blocked angiogenesis by blocking endothelial tube formation by connective tissue growth factor 2 (CCN-2), a protein known for its proangiogenic functions [63]. GDF-15 has shown anti-inflammatory qualities by inhibiting the ability of leukocytes to interact with integrin or arrest along vascular endothelium and by modulating pathways involved in oxidative stress [61,62]. This may be another mechanism by which GDF-15 plays a role in the pathogenesis of DR.

8. Current Research on TGF-β’s Potential Role in DR Treatment

Understanding the mechanisms that the various members of the TGF-β superfamily play in the pathogenesis and progression of DR allows for research regarding potential pharmacologic intervention to prevent onset or delay progression of the disease. One molecule of interest is GDF11, a member of the TGF-β superfamily which has previously been associated with regulation of retinal neurogenesis and promoting angiogenic activity in ischemic limb tissue in diabetic rats [64,65]. Mei et al. studied the actions of supplemental GDF11 in the retinas of diabetic rats to explore the possibility of halting the progression of DR [66]. Results of the study showed that administration of GDF11 was protective against retinal vascular endothelial cell and retinal pericyte apoptosis, two major characteristics of DR. It was also found that pretreatment of the diabetic mice with recombinant GDF11 (rGDF11) reduced the apoptosis of retinal endothelial cells. Pretreated diabetic mice showed an increased expression of anti-apoptotic proteins like Bcl-2 and decreased expression of pro-apoptotic proteins like Bax. Diabetic mice treated with GDF11 also displayed greater blood-retinal barrier (BRB) integrity than the non-treatment diabetic mice. Furthermore, Western blot analysis showed a greater presence of tight junction proteins in the retinas of the treatment diabetic mice, as compared to the non-treatment diabetic mice. Exploration of the possible mechanism behind these results show that GDF11 may promote the canonical TGF-β/SMAD2 pathway, as well as the noncanonical pathways of NF-κB and PI3K-Akt-FoxO.
The utility of targeting TGF-β signaling pathways for the treatment of DR has also been demonstrated in vitro using acrolein, an endogenous compound which has been previously implicated in TGF-β-mediated retinal pigment epithelium (RPE) cell death in the setting of diabetes [66,67,68]. ARPE cells incubated in glucose and acrolein showed significant cell death [68]. However, when these cells are also treated with SIS3, a specific inhibitor of SMAD3, or SB431542, a TGFβR1 antagonist, these results were almost entirely prevented. Not only do these results demonstrate a TGF-β mechanism for acrolein’s damaging effects, but they suggest the value in targeting TGF-β signaling in the treatment of DR [27,68].

9. Conclusions

DR is a complication of diabetes in which damage to retinal cells results in irreversible vision loss. Traditionally thought to be a vascular disease, it is now known to arise from complex and interlinked mechanisms disrupting retinal vasculature, neurons, and immune response. The TGF-β family of proteins consists of several different proteins that participate in signaling pathways, many of which are crucial to retinal integrity and are heavily implicated in DR progression. Numerous studies have explored the molecular mechanisms of the many members of the TGF-β family. However, conflicting results indicate that it is not yet well understood on a molecular level. Current understanding of the downstream effects of TGF-β signaling is complicated by its ubiquity and interaction between numerous cell types. This understanding is important because by expanding the available knowledge on the pathogenesis of DR, more effective pharmacological interventions can be developed to delay or prevent the onset of disease. Recent studies on targeting TGF-β signaling pathways to prevent onset of delay progression of DR have shown promise. Further research is needed, however, to address all various cell types with which the TGF-β proteins interact to gain a more complete understanding of DR progression at the molecular level and develop robust pharmacologic interventions.

Funding

Supported by NIH grants (EY03351; CA278054; DA056203).

Acknowledgments

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045. Ophthalmology. 2021 Nov;128(11):1580–91. [CrossRef]
  2. Aryan N, Betts-Obregon BS, Perry G, Tsin AT. Oxidative Stress Induces Senescence in Cultured RPE Cells. TONEUJ. 2016 Aug 31;10(1):83–7. [CrossRef]
  3. Khan R, Yee Ooi X, Parvus M, Valdez L, Tsin A. Advanced Glycation End Products: Formation, Role in Diabetic Complications, and Potential in Clinical Applications. In: Grigsby J, Derbel F, editors. The Eye and Foot in Diabetes [Internet].. IntechOpen; 2020 [cited 2023 Jun 28].. Available from: https://www.intechopen.com/books/the-eye-and-foot-in-diabetes/advanced-glycation-end-products-formation-role-in-diabetic-complications-and-potential-in-clinical-a.
  4. Akla N, Viallard C, Popovic N, Lora Gil C, Sapieha P, Larrivée B. BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability. ATVB. 2018 Aug;38(8):1821–36.
  5. Grigsby J, Allen D, Ferrigno A, Vellanki S, Pouw C, Hejny W, et al. Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina. CDR. 2017 Feb 17;13(2):161–74. [CrossRef]
  6. Wu MY, Yiang GT, Lai TT, Li CJ. The Oxidative Stress and Mitochondrial Dysfunction during the Pathogenesis of Diabetic Retinopathy. Oxidative Medicine and Cellular Longevity. 2018 Sep 5;2018:1–12. [CrossRef]
  7. Braunger BM, Leimbeck SV, Schlecht A, Volz C, Jägle H, Tamm ER. Deletion of Ocular Transforming Growth Factor β Signaling Mimics Essential Characteristics of Diabetic Retinopathy. The American Journal of Pathology. 2015 Jun;185(6):1749–68. [CrossRef]
  8. Diabetic retinopathy: Prevention and treatment - UpToDate [Internet].. [cited 2023 Jun 29].. Available from: https://www.uptodate.com/contents/diabetic-retinopathy-prevention-and-treatment?search=diabetic%20retinopathy%20treatment&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
  9. Elmasry K, Habib S, Moustafa M, Al-Shabrawey M. Bone Morphogenetic Proteins and Diabetic Retinopathy. Biomolecules. 2021 Apr 18;11(4):593. [CrossRef]
  10. Munk MR, Somfai GM, De Smet MD, Donati G, Menke MN, Garweg JG, et al. The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. IJMS. 2022 Jul 8;23(14):7585. [CrossRef]
  11. Dagher Z, Gerhardinger C, Vaz J, Goodridge M, Tecilazich F, Lorenzi M. The Increased Transforming Growth Factor-β Signaling Induced by Diabetes Protects Retinal Vessels. The American Journal of Pathology. 2017 Mar;187(3):627–38. [CrossRef]
  12. Wheeler SE, Lee NY. Emerging Roles of Transforming Growth Factor β Signaling in Diabetic Retinopathy: TGF-β SIGNALING IN DIABETIC RETINOPATHY. J Cell Physiol. 2017 Mar;232(3):486–9.
  13. Massagué J, Sheppard D. TGF-β signaling in health and disease. Cell. 2023 Sep;186(19):4007–37. [CrossRef]
  14. Huang, H. Pericyte-Endothelial Interactions in the Retinal Microvasculature. IJMS. 2020 Oct 8;21(19):7413. [CrossRef]
  15. Kim KS, Park JM, Kong T, Kim C, Bae SH, Kim HW, et al. Retinal Angiogenesis Effects of TGF-β1 and Paracrine Factors Secreted from Human Placental Stem Cells in Response to a Pathological Environment. Cell Transplant. 2016 Jun;25(6):1145–57. [CrossRef]
  16. Hachana S, Larrivée B. TGF-β Superfamily Signaling in the Eye: Implications for Ocular Pathologies. Cells. 2022 Jul 29;11(15):2336. [CrossRef]
  17. Nickel J, Ten Dijke P, Mueller TD. TGF-β family co-receptor function and signaling. ABBS. 2018 Jan 1;50(1):12–36. [CrossRef]
  18. Liu RM, Desai LP. Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis. Redox Biology. 2015 Dec;6:565–77. [CrossRef]
  19. Zhang, YE. Non-Smad Signaling Pathways of the TGF-β Family. Cold Spring Harb Perspect Biol. 2017 Feb;9(2):a022129. [CrossRef]
  20. Schoonderwoerd MJA, Goumans MJTH, Hawinkels LJAC. Endoglin: Beyond the Endothelium. Biomolecules. 2020 Feb 12;10(2):289. [CrossRef]
  21. Shu DY, Lovicu FJ. Insights into Bone Morphogenetic Protein—(BMP-) Signaling in Ocular Lens Biology and Pathology. Cells. 2021 Sep 30;10(10):2604. [CrossRef]
  22. Zorena K, Raczyńska D, Raczyńska K. Biomarkers in Diabetic Retinopathy and the Therapeutic Implications. Mediators of Inflammation. 2013;2013:1–11. [CrossRef]
  23. Bonfiglio V, Platania CBM, Lazzara F, Conti F, Pizzo C, Reibaldi M, et al. TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy. IJMS. 2020 Dec 15;21(24):9558. [CrossRef]
  24. Liu Y, Paauwe M, Nixon AB, Hawinkels LJAC. Endoglin Targeting: Lessons Learned and Questions That Remain. IJMS. 2020 Dec 25;22(1):147. [CrossRef]
  25. Desroches-Castan A, Tillet E, Bouvard C, Bailly S. BMP9 and BMP10 : Two close vascular quiescence partners that stand out. Developmental Dynamics. 2022 Jan;251(1):158–77. [CrossRef]
  26. Beránek M, Kanková K, Benes P, Izakovicová-Hollá L, Znojil V, Hájek D, et al. Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy. Am J Med Genet. 2002 May 15;109(4):278–83.
  27. Wang M, Sheng KJ, Fang JC, Zhao H, Lu SM, Liu ZY, et al. Redox signaling in diabetic retinopathy and opportunity for therapeutic intervention through natural products. European Journal of Medicinal Chemistry. 2022 Dec;244:114829. [CrossRef]
  28. Rodriguez R, Lowe K, Keniry M, Tsin A. Involvement of TGFβ signaling pathway in oxidative stress and diabetic retinopathy. Arch Clin Exp Ophthalmol. 2021;3(2):23–8.
  29. Khuu LA, Tayyari F, Sivak JM, Flanagan JG, Singer S, Brent MH, et al. Aqueous humour concentrations of TGF- β, PLGF and FGF-1 and total retinal blood flow in patients with early non-proliferative diabetic retinopathy. Acta Ophthalmol. 2017 May;95(3):e206–11.
  30. McAuley AK, Sanfilippo PG, Hewitt AW, Liang H, Lamoureux E, Wang JJ, et al. Vitreous biomarkers in diabetic retinopathy: A systematic review and meta-analysis. Journal of Diabetes and its Complications. 2014 May;28(3):419–25. [CrossRef]
  31. Liu L, Jiao J, Wang Y, Wu J, Huang D, Teng W, et al. TGF-beta1 Gene Polymorphism in Association with Diabetic Retinopathy Susceptibility: A Systematic Review and Meta-Analysis. Ljubimov AV, editor. PLoS ONE. 2014 Apr 7;9(4):e94160. [CrossRef]
  32. Li Q, Pang L, Yang W, Liu X, Su G, Dong Y. Long Non-Coding RNA of Myocardial Infarction Associated Transcript (LncRNA-MIAT) Promotes Diabetic Retinopathy by Upregulating Transforming Growth Factor-β1 (TGF-β1) Signaling. Med Sci Monit. 2018 Dec 31;24:9497–503.
  33. Shao K, Xi L, Cang Z, Chen C, Huang S. Knockdown of NEAT1 exerts suppressive effects on diabetic retinopathy progression via inactivating TGF-β1 and VEGF signaling pathways. Journal Cellular Physiology. 2020 Dec;235(12):9361–9. [CrossRef]
  34. Saucedo L, Pfister IB, Zandi S, Gerhardt C, Garweg JG. Ocular TGF-β, Matrix Metalloproteinases, and TIMP-1 Increase with the Development and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus. Yokota S ichi, editor. Mediators of Inflammation. 2021 Jun 25;2021:1–10. [CrossRef]
  35. Guo J, Zhou P, Pan M, Liu Z, An G, Han J, et al. Relationship between elevated microRNAs and growth factors levels in the vitreous of patients with proliferative diabetic retinopathy. Journal of Diabetes and its Complications. 2021 Nov;35(11):108021. [CrossRef]
  36. Walshe TE, Saint-Geniez M, Maharaj ASR, Sekiyama E, Maldonado AE, D’Amore PA. TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult Microvasculature. PLOS ONE. 2009 Apr 2;4(4):e5149. [CrossRef]
  37. Pardali E, Goumans MJ, ten Dijke P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 2010 Sep;20(9):556–67.
  38. Yang H, Huang Y, Chen X, Liu J, Lu Y, Bu L, et al. The role of CTGF in the diabetic rat retina and its relationship with VEGF and TGF-β2, elucidated by treatment with CTGFsiRNA. Acta Ophthalmologica. 2010 Sep;88(6):652–9.
  39. Xue L, Xiong C, Li J, Ren Y, Zhang L, Jiao K, et al. miR-200-3p suppresses cell proliferation and reduces apoptosis in diabetic retinopathy via blocking the TGF-β2/Smad pathway. Bioscience Reports. 2020 Nov 27;40(11):BSR20201545.
  40. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res. 2007 May;84(5):812–22.
  41. Dai Y, Wu Z, Wang F, Zhang Z, Yu M. Identification of Chemokines and Growth Factors in Proliferative Diabetic Retinopathy Vitreous. BioMed Research International. 2014;2014:1–9. [CrossRef]
  42. Al-Shabrawey M, Hussein K, Wang F, Wan M, Elmasry K, Elsherbiny N, et al. Bone Morphogenetic Protein-2 Induces Non-Canonical Inflammatory and Oxidative Pathways in Human Retinal Endothelial Cells. Front Immunol. 2021 Jan 29;11:568795. [CrossRef]
  43. Vogt RR, Unda R, Yeh LCC, Vidro EK, Lee JC, Tsin AT. Bone morphogenetic protein-4 enhances vascular endothelial growth factor secretion by human retinal pigment epithelial cells. J Cell Biochem. 2006 Aug 1;98(5):1196–202. [CrossRef]
  44. Nagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wiggert B, Detrick B, et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol. 2003 Dec;197(3):453–62.
  45. Heinke J, Wehofsits L, Zhou Q, Zoeller C, Baar KM, Helbing T, et al. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res. 2008 Oct 10;103(8):804–12. [CrossRef]
  46. Betts-Obregon BS, Mondragon AA, Mendiola AS, LeBaron RG, Asmis R, Zou T, et al. TGFβ induces BIGH3 expression and human retinal pericyte apoptosis: a novel pathway of diabetic retinopathy. Eye (Lond). 2016 Dec;30(12):1639–47. [CrossRef]
  47. Hong S, Lim S, Li AG, Lee C, Lee YS, Lee EK, et al. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat Immunol. 2007 May;8(5):504–13. [CrossRef]
  48. Mondragon AA, Betts-Obregon BS, Moritz RJ, Parvathaneni K, Navarro MM, Kim HS, et al. BIGH3 protein and Macrophages in Retinal Endothelial Cell Apoptosis. Apoptosis. 2015 Jan;20(1):29–37. [CrossRef]
  49. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25;7(315):315ra189. [CrossRef]
  50. Zhang S, Gang X, Yang S, Cui M, Sun L, Li Z, et al. The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases. Front Immunol. 2021;12:678355.
  51. Rudensky AY. Regulatory T Cells and Foxp3. Immunol Rev. 2011 May;241(1):260–8.
  52. Yang TT, Song SJ, Xue HB, Shi DF, Liu CM, Liu H. Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by miR-155. European Review for Medical and Pharmacological Sciences. 2015 Jun 15;19(11):2010–5.
  53. Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. Int J Mol Sci. 2018 Jun 20;19(6):1816. [CrossRef]
  54. Chen HY, Ho YJ, Chou HC, Liao EC, Tsai YT, Wei YS, et al. The Role of Transforming Growth Factor-Beta in Retinal Ganglion Cells with Hyperglycemia and Oxidative Stress. IJMS. 2020 Sep 4;21(18):6482. [CrossRef]
  55. Chen HY, Ho YJ, Chou HC, Liao EC, Tsai YT, Wei YS, et al. TGF-β1 signaling protects retinal ganglion cells from oxidative stress via modulation of the HO-1/Nrf2 pathway. Chem Biol Interact. 2020 Nov 1;331:109249.
  56. Khalid M, Petroianu G, Adem A. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules. 2022 Apr 4;12(4):542. [CrossRef]
  57. Vidro-Kotchan E, Yendluri BB, Le-Thai T, Tsin A. NBHA Reduces Acrolein-Induced Changes in ARPE-19 Cells: Possible Involvement of TGFβ. Current Eye Research. 2011 Apr;36(4):370–8. [CrossRef]
  58. Vidro EK, Gee S, Unda R, Ma J xing, Tsin A. Glucose and TGFβ2 Modulate the Viability of Cultured Human Retinal Pericytes and Their VEGF Release. Current Eye Research. 2008 Jan;33(11–12):984–93. [CrossRef]
  59. Sánchez-de-Diego C, Valer JA, Pimenta-Lopes C, Rosa JL, Ventura F. Interplay between BMPs and Reactive Oxygen Species in Cell Signaling and Pathology. Biomolecules. 2019 Sep 26;9(10):534. [CrossRef]
  60. Wu L, Li J, Zhao F, Xiang Y. MiR-340-5p inhibits Müller cell activation and pro-inflammatory cytokine production by targeting BMP4 in experimental diabetic retinopathy. Cytokine. 2022 Jan;149:155745. [CrossRef]
  61. Niu Y, Zhang W, Shi J, Liu Y, Zhang H, Lin N, et al. The Relationship Between Circulating Growth Differentiation Factor 15 Levels and Diabetic Retinopathy in Patients With Type 2 Diabetes. Front Endocrinol. 2021 Mar 15;12:627395. [CrossRef]
  62. Chung JO, Park SY, Cho DH, Chung DJ, Chung MY. Relationship between plasma growth differentiation factor-15 levels and diabetic retinopathy in individuals with type 2 diabetes. Sci Rep. 2020 Nov 25;10(1):20568. [CrossRef]
  63. Whitson RJ, Lucia MS, Lambert JR. Growth differentiation factor-15 (GDF-15) suppresses in vitro angiogenesis through a novel interaction with connective tissue growth factor (CCN2). J Cell Biochem. 2013 Jun;114(6):1424–33. [CrossRef]
  64. Kim J, Wu HH, Lander AD, Lyons KM, Matzuk MM, Calof AL. GDF11 Controls the Timing of Progenitor Cell Competence in Developing Retina. Science. 2005 Jun 24;308(5730):1927–30. [CrossRef]
  65. Zhang J, Li Y, Li H, Zhu B, Wang L, Guo B, et al. GDF11 Improves Angiogenic Function of EPCs in Diabetic Limb Ischemia. Diabetes. 2018 Oct 1;67(10):2084–95. [CrossRef]
  66. Mei W, Zhu B, Shu Y, Liang Y, Lin M, He M, et al. GDF11 protects against glucotoxicity-induced mice retinal microvascular endothelial cell dysfunction and diabetic retinopathy disease. Molecular and Cellular Endocrinology. 2021 Nov 1;537:111422. [CrossRef]
  67. Curtis TM, Hamilton R, Yong PH, McVicar CM, Berner A, Pringle R, et al. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia. 2011 Mar;54(3):690–8. [CrossRef]
  68. Grigsby J, Betts B, Vidro-Kotchan E, Culbert R, Tsin A. A Possible Role of Acrolein in Diabetic Retinopathy: Involvement of a VEGF/TGFβ Signaling Pathway of the Retinal Pigment Epithelium in Hyperglycemia. Current Eye Research [Internet].. 2012 Nov 1 [cited 2023 Dec 5].; Available from: https://www.tandfonline.com/doi/full/10.3109/02713683.2012.713152. [CrossRef]
Preprints 97240 g001
Figure 1. Summary of the current understanding of TGF-β roles in diabetic retinopathy. TGF-β is understood to be pervasively crucial to retinal homeostasis and is closely associated with the pathogenesis of diabetic retinopathy across multiple cell types and interactions. However, the precise action of each TGF-β superfamily members remains largely unclear. Diabetic complications encompass the myriad of destructive mechanisms that contribute to diabetic retinopathy, like hyperglycemia and immune response. Positive associations are denoted by the arrowhead (↓), and negative associations are denoted by the inhibitory arrow (I).
Figure 1. Summary of the current understanding of TGF-β roles in diabetic retinopathy. TGF-β is understood to be pervasively crucial to retinal homeostasis and is closely associated with the pathogenesis of diabetic retinopathy across multiple cell types and interactions. However, the precise action of each TGF-β superfamily members remains largely unclear. Diabetic complications encompass the myriad of destructive mechanisms that contribute to diabetic retinopathy, like hyperglycemia and immune response. Positive associations are denoted by the arrowhead (↓), and negative associations are denoted by the inhibitory arrow (I).
Preprints 97240 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Transthyretin Upregulates Long Non-Coding RNA MEG3 by Affecting PABPC1 in Diabetic Retinopathy

Guangming Fan

et al.

IJMS,

2019

TGFβ1 Induces Senescence and Attenuated VEGF Production in Retinal Pericytes

Dragana Avramovic

et al.

Biomedicines,

2022

Loss of Response Gene to Complement 32 (RGC-32) in Diabetic Mouse Retina Is Involved in Retinopathy Development

Wen-Ling Liao

et al.

IJMS,

2018

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated